Norwood Abbey specialises in developing and commercialising innovative projects and technologies that address significant unmet needs in the medical industry.

Norwood is developing its technologies in collaboration with pre-eminent Australian and international clinical research institutions and commercial partners. Together Norwood and its partners are applying the technology platforms to address some of today's most challenging and complex clinical problems.

Norwood’s strategy is to establish key strategic alliances and partnerships with the objective of improving people's lives.

 

Norwood Abbey .........................

"Partnerships to Improve People's Lives"

11/20/2008 - Results Of Meeting



10/29/2008 - Appendix 4C Quarterly



10/27/2008 - Further Micro-Needle Patent Granted in USA



10/20/2008 - 2008 Annual Report



9/30/2008 - Further Fundraising Completed



9/26/2008 - NIM Stem Cell Developments



9/22/2008 - Russian Federation Eyecare Patent



9/15/2008 - Debt to Equity Conversions



9/15/2008 - Completion of Fundraising



7/17/2008 - Medimmune: Exclusive agreement with Virosome



5/21/2008 - US Microneedle Patent granted



4/21/2008 - GEM Equity Line Facility Extension



1/31/2008 - Spin Out of Neede-free Injection Technology



12/24/2007 - Norwood Immunology Update



10/25/2007 - Results Of Renounceable Rights Issue



9/12/2007 - Needle-Free Injection Patent Granted



5/3/2007 - Microneedle Patent Granted



4/23/2007 - Needle-Free Injection Project Restructure



4/17/2007 - Needle-Free Injection - Vaccine Breakthrough



4/4/2007 - Needle-Free Controlled Depth Video